By the way, I should mention this is not a contraindication, its just something to be aware of
Whilst the market is currently led by Novo Nordisks semaglutide (Ozempic/Wegovy) and Eli Lillys tirzepatide (Mounjaro/Zepbound), stronger competition is expected with new entrants (Boehringer Ingelheim, Amgen, Pfizer, Roche amongst others) offering novel mechanisms (dual agonists, triple agonists and amylins), formulations (oral vs injectable) and dosing regimens (daily vs weekly vs monthly).
What am I getting: 1-month supply of compounded tirzepatide
Once your body produces GLP-1 in response to glycine and alanine, theres nothing in plain gelatin that makes that signal stronger or longer-lasting beyond the baseline DPP-IV inhibition from peptides
The main representative drug of it is tirzepatide [135], which is a representative dual agonist commonly studied